Codexis, Inc. develops enzyme-based solutions for therapeutics manufacturing, using its CodeEvolver technology to discover and improve high-performance enzymes. Company news commonly covers financial results, guidance, cash-runway commentary, and business updates tied to small molecule pharmaceutical biocatalysis, nucleic acid synthesis, and the ECO Synthesis manufacturing platform for enzymatic RNAi and siRNA production.
Recurring developments include partner and evaluation agreements, technology-transfer activity, quality-system and manufacturing-suite updates, conference data on ECO Synthesis capabilities such as phosphorothioate stereochemistry and ligation efficiency, and portfolio updates for enzymes used in branded pharmaceutical products.
Codexis (NASDAQ: CDXS) reported Q1 2026 revenue of $15.2 million and reiterated full‑year guidance of $72–$76 million. Product gross margin was 71%; net loss narrowed to $8.7 million ($0.10/share). Cash and short‑term investments totaled $65.1 million, which the company says funds operations through end of 2027.
The company highlighted ECO Synthesis® platform progress, three upcoming TIDES presentations on siRNA stereochemistry and ligation, a 50g siRNA supply agreement for pre‑IND studies, ISO 9001 certification, and plans for an ECO GMP Manufacturing Center.
Codexis (NASDAQ: CDXS) will present RNA manufacturing advances at TIDES USA, May 11–14 in Boston. Presentations cover ECO Synthesis® platform results on phosphorothioate stereochemistry control, ligation efficiency, process performance, and sustainability. Codexis will host a panel and maintain a booth (821) during the conference.
Codexis (NASDAQ: CDXS) will report Q1 2026 financial results on May 7, 2026 after market close. Management will host a conference call and webcast at 4:30 PM ET to discuss results and provide a business update. The live webcast will be archived for 90 days; telephone replay available for 48 hours (Access ID #13726635).
Codexis (NASDAQ: CDXS) reported fourth-quarter revenue of $38.9M and fiscal 2025 total revenue of $70.4M. The company ended 2025 with $78.2M in cash and expects runway through 2027. Fiscal 2025 saw product gross margin of 64% and a net loss of $44.0M.
Q4 growth was driven by a $37.8M Technology Transfer Agreement with Merck and momentum in ECO Synthesis commercial engagements; the company provided 2026 revenue guidance of $72M–$76M.
Codexis (NASDAQ: CDXS) announced on March 4, 2026 an agreement to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support a partner's preclinical cardiovascular program.
The engagement is presented as a demonstration of the platform's ability to produce material beyond early research volumes and as a potential pathway to further scale-up and commercial manufacturing, subject to program advancement.
Codexis (NASDAQ: CDXS) will report fourth quarter and fiscal year 2025 results on Wednesday, March 11, 2026 after market close. Management will host a conference call and webcast at 4:30 PM ET to discuss results and provide a business update.
The live webcast will be available on the Codexis Investor Relations website and archived for 90 days; a telephone replay will be available for 48 hours.
Codexis (NASDAQ: CDXS) will attend the TD Cowen 46th Annual Health Care Conference in Boston March 2-4, 2026. Management will join a fireside chat on March 3, 2026 at 11:50 am ET. A live webcast will be available on the company's Investor Relations site and replayed for 90 days.
Codexis (Nasdaq: CDXS) announced it earned ISO 9001:2015 certification on February 10, 2026, covering its Redwood City headquarters, R&D, process development labs including the ECO Synthesis Innovation Laboratory, and its non‑GMP manufacturing facility.
The certification recognizes Codexis’s documented quality management system for design, development, manufacturing, delivery, and support, and signals a commitment to continuous quality improvement in its biomanufacturing products and services.
Codexis (NASDAQ: CDXS) and Axolabs announced an evaluation agreement dated January 7, 2026, under which Axolabs will test Codexis' ECO Synthesis Manufacturing Platform for enzymatic RNA/oligonucleotide production.
The agreement gives Axolabs access to Codexis' scalable enzymatic synthesis technology and may lead to future licensing discussions and broader platform adoption if evaluation results are favourable. Both companies described the collaboration as advancing efficient, sustainable manufacturing of oligonucleotide therapeutics and expanding access to high-quality oligonucleotide medicines.
Codexis (NASDAQ: CDXS) signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California to expand internal GMP production capabilities.
The multi-purpose site will enable GMP manufacturing of siRNA and other oligonucleotides using the company's ECO Synthesis platform, start modifications in early 2026, and can be adapted to scale production of purified enzymes that support the platform. The company said the facility will support early clinical trial manufacturing and provide flexible capacity for evolving business needs.